Education
About Us
Working with TipRanks
Follow Us
AIM ImmunoTech Inc (AIM)
:AIM
Top Page
AIM ImmunoTech
(NYSE MKT:AIM)
35Underperform
Positive Factors
Clinical Trials
Positive data announced from Phase 2 study evaluating Ampligen as a therapeutic for patients with post-COVID conditions could boost stock value.
Financial Stability
The balance sheet shows $7 million in cash and only $3 million in debt, suggesting financial stability into mid-2025.
Product Development
Ampligen targets moderate-to-severe fatigue in long COVID, addressing a significant area of unmet need with potential political support.
Negative Factors
Corporate Governance
Dissident stockholders have nominated their own slate of directors for the third consecutive year, indicating potential ongoing governance challenges.
Stock Valuation
Factoring in the dilution lowers the 12-month price target to $1.00, from $2.00.
AIM ImmunoTech (AIM) vs. S&P 500 (SPY)
Market Cap
$2.91M
Dividend YieldN/A
Average Volume (3M)769.77K
Price to Earnings (P/E)―
Beta (1Y)1.57
Revenue Growth-15.84%
EPS Growth47.31%
CountryUS
Employees21
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.31
Shares Outstanding72,290,030
10 Day Avg. Volume617,493
30 Day Avg. Volume769,771
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)47.61
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4.50Price Target Upside11150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
AIM ImmunoTech Business Overview & Revenue Model
Company DescriptionAIM ImmunoTech (AIM) is a biotechnology company focused on the research and development of therapeutics to treat immune system disorders, viral diseases, and certain types of cancers. The company's core products include Ampligen, a drug that is being explored for its potential to enhance the immune response in various clinical settings. AIM ImmunoTech operates primarily in the biopharmaceutical sector, working on advancing its pipeline of immune-related therapies.
How the Company Makes MoneyAIM ImmunoTech makes money primarily through partnerships, licensing agreements, and grants related to its proprietary drug, Ampligen. The company seeks to monetize its research and development efforts by collaborating with other pharmaceutical companies, which may include receiving upfront payments, milestone payments, and royalties based on product sales. Additionally, AIM may receive revenue from government and private research grants that support the development of its therapies. The company's revenue streams are significantly influenced by the progress of clinical trials and regulatory approvals of its key products.
AIM ImmunoTech Financial Statement Overview
Summary
AIM ImmunoTech faces significant financial challenges, with declining revenues, high operating losses, and increasing leverage. The cash flow issues further compound these problems, raising concerns about its ability to sustain operations without external funding or significant improvements.Income Statement
AIM ImmunoTech's income statement for TTM shows a declining revenue trend with a negative gross profit margin, indicating a lack of profitability. The company is experiencing significant operating losses as evident from negative EBIT and EBITDA margins, which are concerning signals for financial health.20
Very Negative
Balance Sheet
The balance sheet highlights a challenging financial position with a low equity ratio. The debt-to-equity ratio has increased over time, showing potential risk due to higher leverage. The company's total assets have significantly decreased, affecting its financial stability.35
Negative
Cash Flow
Cash flow analysis reveals negative free cash flow, indicating that the company is spending more cash than it generates. The operating cash flow to net income ratio is negative, suggesting inefficiencies in converting income into cash. The trend of negative cash flows presents liquidity concerns.25
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 190.00K | 202.00K | 141.00K | 135.00K | 163.00K | 140.00K | Gross Profit |
| 38.00K | 160.00K | -19.78M | -715.00K | -643.00K | -753.00K | EBIT |
| -27.91M | -31.92M | -19.92M | -18.84M | -15.15M | -12.44M | EBITDA |
| -24.66M | -31.68M | -19.87M | -18.25M | -13.02M | -8.15M | Net Income Common Stockholders |
| -23.93M | -28.96M | -21.09M | -21.51M | -16.26M | -10.83M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 1.82M | 13.07M | 34.19M | 48.27M | 39.00M | 8.78M | Total Assets |
| 13.85M | 19.38M | 40.49M | 57.70M | 64.58M | 20.22M | Total Debt |
| 5.92M | 718.00K | 837.00K | 149.00K | 2.29M | 6.38M | Net Debt |
| 5.63M | -4.72M | -26.22M | -31.94M | -36.22M | 4.91M | Total Liabilities |
| 8.67M | 9.15M | 2.02M | 820.00K | 3.29M | 7.31M | Stockholders Equity |
| 5.17M | 10.23M | 38.47M | 56.88M | 61.29M | 12.91M |
| Cash Flow | Free Cash Flow | ||||
| -21.33M | -21.85M | -16.38M | -14.60M | -10.96M | -9.43M | Operating Cash Flow |
| -20.69M | -21.27M | -16.11M | -13.96M | -10.37M | -9.07M | Investing Cash Flow |
| 788.00K | -832.00K | 10.99M | -631.00K | -9.16M | -6.15M | Financing Cash Flow |
| 5.55M | 485.00K | 80.00K | 8.19M | 56.56M | 16.39M |
AIM ImmunoTech Technical Analysis
Negative
0.04
Price Trends
0.14
Negative
0.18
Negative
0.25
Negative
Market Momentum
>-0.01
Negative
39.56
Neutral
17.47
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIM, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.14, and below the 200-day MA of 0.25, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 39.56 is Neutral, neither overbought nor oversold. The STOCH value of 17.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AIM.
AIM ImmunoTech Risk Analysis
AIM ImmunoTech disclosed 33 risk factors in its most recent earnings report. AIM ImmunoTech reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AIM ImmunoTech Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
48 Neutral | $6.27B | 1.17 | -48.19% | 2.68% | 17.28% | 1.24% | |
39 Underperform | $5.62M | ― | -233.67% | ― | ― | ― | |
38 Underperform | $7.23M | ― | -534.03% | ― | ― | 23.65% | |
35 Underperform | $2.91M | ― | -388.69% | ― | -15.84% | 47.31% | |
29 Underperform | $6.85M | ― | -187.52% | ― | ― | 11.97% |
* Healthcare Sector Average
Performance Comparison
AIM
AIM ImmunoTech
0.04
-0.52
-92.86%
INDP
Indaptus Therapeutics
0.49
-2.03
-80.56%
ACXP
Acurx Pharmaceuticals
0.30
-1.56
-83.87%
APLM
Apollomics
5.15
-49.95
-90.65%
AIM ImmunoTech Earnings Call Summary
Earnings Call Date: Mar 27, 2025 | % Change Since: -69.23% | Next Earnings Date: May 15, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant clinical and strategic advancements, including new studies, leadership expansion, and cost reductions. However, financial challenges were noted, with low cash reserves and a risk of delisting from the stock exchange, which the company is actively working to address.Highlights
New Clinical Study with AstraZeneca
AIM ImmunoTech announced plans to conduct a new clinical study evaluating Ampligen in combination with AstraZeneca's intranasal influenza vaccine, FluMist, for influenza, including avian flu.
Leadership Expansion
The company strengthened its leadership with the addition of two Board members, Ted Kellner and David Chemerow, bringing extensive investment and financial expertise.
Approval for Phase 2 Pancreatic Cancer Trial
Continuation into the Phase 2 portion of the DURIPANC pancreatic cancer trial has been approved, with dosing commenced, marking a key advancement in this program.
Publication and Patent Advancements
A new U.S. patent was granted for the treatment of endometriosis, and a Netherlands patent for post-COVID fatigue. Also, new data was published from a study in early-stage triple negative breast cancer.
R&D Cost Reduction
Research and development expenses decreased from $10.9 million in 2023 to $6.2 million in 2024, indicating more efficient use of resources.
G&A Expenses Reduction
General and administrative expenses decreased from $21.1 million in 2023 to $13.7 million in 2024, reflecting improved operational efficiency.
Lowlights
Low Cash Reserves
As of December 31, 2024, AIM ImmunoTech had approximately $4 million in cash, cash equivalents, and marketable securities, highlighting potential financial constraints.
Continued Listing Risk
The company is at risk of being delisted from the New York Stock Exchange American and is considering a reverse stock split to maintain compliance.
Company Guidance
During the AIM ImmunoTech Fourth Quarter and Full Year 2024 Update Conference Call, CEO Thomas Equels provided extensive guidance on the company's progress and future plans. Key clinical updates included the continuation into Phase 2 of the DURIPANC trial evaluating Ampligen with AstraZeneca's Imfinzi for metastatic pancreatic cancer, and the completion of the AMP-518 study on post-COVID conditions. Financial metrics revealed that research and development expenses decreased to $6.2 million from $10.9 million the previous year, while general and administrative expenses fell to $13.7 million from $21.1 million. The company held approximately $4 million in cash and equivalents as of December 31, 2024. Strategic initiatives to maintain NYSE American listing, including a potential reverse stock split, were also discussed. The call concluded with a commitment to advancing Ampligen's potential across several high-need medical areas.AIM ImmunoTech Corporate Events
Executive/Board ChangesShareholder MeetingsBusiness Operations and Strategy
AIM ImmunoTech Appoints David Chemerow to Board
Neutral
Feb 26, 2025
AIM ImmunoTech Inc. announced the appointment of David I. Chemerow to its Board of Directors, effective February 24, 2025. Mr. Chemerow brings over 40 years of experience in finance, accounting, and operations across multiple industries, having held significant roles at Comscore, Inc. and Rentrak Corporation. His appointment is expected to enhance AIM’s strategic direction as the company continues to advance its mission in the immuno-pharma space. Additionally, AIM has amended its bylaws to reduce the quorum for stockholder meetings from 40% to 33 and 1/3%.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.